Prothena Corp Public (PRTA) Long-Term Deferred Tax (2012 - 2025)
Prothena Corp Public (PRTA) recorded quarterly Long-Term Deferred Tax of $44.9 million in Q1 2025, up 3.87% quarter-over-quarter from $43.2 million in Q4 2024, and up 22.46% on a YoY basis from $36.7 million in Q1 2024.
Prothena Corp Public (PRTA) Long-Term Deferred Tax (2012 - 2025) Analysis & Trends
Prothena Corp Public's Long-Term Deferred Tax history runs 14 years deep, the most recent figure standing at $44.9 million for Q1 2025.
- In Q1 2025, Long-Term Deferred Tax rose 22.46% year-over-year to $44.9 million; the TTM figure through Mar 2025 stood at $44.9 million (up 22.46% YoY), while the FY2024 annual figure was $43.2 million, up 27.58% from the prior year.
- Long-Term Deferred Tax was $44.9 million for Q1 2025 at Prothena Corp Public, up from $43.2 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $44.9 million in Q1 2025 to a low of $6.4 million in Q2 2021.
- Historically, Long-Term Deferred Tax has averaged $23.4 million across 5 years, with a median of $21.4 million in 2023.
- The sharpest annual moves came in 2021 and 2022: Long-Term Deferred Tax slumped 43.57% in 2021, then jumped 157.45% in 2022.
- A 5-year view of Long-Term Deferred Tax shows it stood at $7.1 million in 2021, then surged by 157.45% to $18.2 million in 2022, then soared by 86.18% to $33.9 million in 2023, then gained by 27.58% to $43.2 million in 2024, then climbed by 3.87% to $44.9 million in 2025.
- The last three Long-Term Deferred Tax figures came in at $44.9 million (Q1 2025), $43.2 million (Q4 2024), and $41.0 million (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 44.91 Mn |
| Dec 31, 2024 | 43.24 Mn |
| Sep 30, 2024 | 41.00 Mn |
| Jun 30, 2024 | 39.48 Mn |
| Mar 31, 2024 | 36.68 Mn |
| Dec 31, 2023 | 33.89 Mn |
| Sep 30, 2023 | 29.92 Mn |
| Jun 30, 2023 | 25.94 Mn |
| Mar 31, 2023 | 21.43 Mn |
| Dec 31, 2022 | 18.20 Mn |
| Sep 30, 2022 | 14.97 Mn |
| Jun 30, 2022 | 11.96 Mn |
| Mar 31, 2022 | 9.59 Mn |
| Dec 31, 2021 | 7.07 Mn |
| Sep 30, 2021 | 6.50 Mn |
| Jun 30, 2021 | 6.43 Mn |
| Mar 31, 2021 | 7.02 Mn |
| Dec 31, 2020 | 11.64 Mn |
| Sep 30, 2020 | 11.52 Mn |
| Jun 30, 2020 | 11.02 Mn |